FDAsafety guidance65% confidence
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Merck.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · BCR::ABL1 Inhibition
- Sub-indication
- General
Related signal: Merck Acquires Terns Pharmaceuticals, Enhancing Oncology Pipeline with TERN-701